U.S. Markets open in 7 hrs 1 min
  • S&P Futures

    3,902.00
    +4.25 (+0.11%)
     
  • Dow Futures

    31,241.00
    +39.00 (+0.12%)
     
  • Nasdaq Futures

    11,838.00
    -40.25 (-0.34%)
     
  • Russell 2000 Futures

    1,771.50
    -3.40 (-0.19%)
     
  • Crude Oil

    110.35
    +0.46 (+0.42%)
     
  • Gold

    1,845.10
    +3.90 (+0.21%)
     
  • Silver

    21.87
    -0.03 (-0.13%)
     
  • EUR/USD

    1.0562
    -0.0026 (-0.2429%)
     
  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     
  • Vix

    29.43
    +0.08 (+0.27%)
     
  • GBP/USD

    1.2495
    +0.0020 (+0.1587%)
     
  • USD/JPY

    127.8500
    +0.0560 (+0.0438%)
     
  • BTC-USD

    29,617.25
    -74.00 (-0.25%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

CureVac Outlines Upcoming Catalysts For Vaccine Programs

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Ahead of J.P. Morgan Healthcare Conference, CureVac BV (NASDAQ: CVAC) outlined the timeline for its vaccine programs.

  • CureVac's preclinical second-generation mRNA vaccine candidate, CV2CoV, against SARS-CoV-2 is under development in collaboration with GlaxoSmithKline Plc (NYSE: GSK).

  • The company expects to start a Phase 1 trial assessing CV2CoV in Q1 2022.

  • Related: CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal Study.

  • Additionally, the company expects to start assessing a modified second-generation COVID-19 mRNA vaccine candidate in a Phase 1 trial in Q3 2022.

  • The company conservatively estimates that a pivotal study for COVID-19 vaccine candidate may start in Q4 2022.

  • CureVac, in collaboration with GSK, is also working on an influenza vaccine. The company expects to start a Phase 1 trial with a chemically non-modified mRNA candidate in Q1 2022 and a Phase 1 trial with a modified mRNA candidate in Q3 2022.

  • Comprehensive data from the expansion part of CureVac's lead oncology candidate, CV8102, is expected to be published in Q4 2022.

  • Furthermore, the company anticipates providing proof-of-concept data for selected antigens in cancer vaccines, focusing on T cell-mediated responses in the future.

  • The suitable clinical candidate(s) for a first clinical study will occur in 1H 2022.

  • Price Action: CVAC shares closed 0.36% higher at $30.68 on Friday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.